Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC in non-COVID-19 ARDS
NCT04909879Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of COVI-MSC in acute respiratory distress syndrome (ARDS), sponsored by Sorrento Therapeutics. Planned start Sep 2021; status: withdrawn.
02
Drugs
COVI-MSC
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04909879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909879.